EUVIMEDEUVIMED entdecken
Crossref

Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer

Luca Antonelli, Davide Ardizzone, Isamu Tachibana iD, Nabil Adra iD, Clint Cary iD, Lee Hugar, Wade J Sexton iD, Aditya Bagrodia iD, Michal Mego, Siamak Daneshmand iD, Nicola Nicolai, Sebastiano Nazzani iD und 20 weitere

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.23.00443 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Luca Antonelli und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland. Hauptthemen laut MEDLINE: Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

What is the role of pcRPLND in men with retroperitoneal vital cancer after first-line chemotherapy? This question arises because of the potential predictive value of miR371 in identifying residual cancer even before pcRPLND! @cdfankhauser shared data within a multicenter cohort study redefining future practice in the miR371 era.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Testicular NeoplasmsNeoplasms, Germ Cell and EmbryonalMaleHumansFemaleNeoplasm, ResidualRetrospective StudiesLymph Node ExcisionRetroperitoneal SpaceRisk FactorsRecurrenceTreatment Outcome

Autor:innen und Institutionen

  • Department of Urology, Luzerner Kantonsspital, University of Lucerne, Lucerne, Switzerland.
  • Department of Urology, Policlinico Umberto I, Sapienza University, Rome, Italy.
  • University of Lucerne, Lucerne, Switzerland.
  • Department of Urology, Indiana University School of Medicine, Indianapolis, IN.
  • Division of Medical Oncology, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL.

ORCID-Profile: Isamu Tachibana, Nabil Adra, Clint Cary, Wade J Sexton, Aditya Bagrodia, Siamak Daneshmand, Sebastiano Nazzani, Andrea Franza, Axel Heidenreich, Ragheed Saoud, Scott Eggener, Alexey Tryakin, Mikhail Fedyanin, Walter Cazzaniga, Axel Gerdtsson, Karim Fizazi, Christian Daniel Fankhauser

Zitieren

APA

Antonelli, L., Ardizzone, D., Tachibana, I., Adra, N., Cary, C., Hugar, L., Sexton, W. J., Bagrodia, A., Mego, M., Daneshmand, S., Nicolai, N., Nazzani, S., Giannatempo, P., Franza, A., Heidenreich, A., Paffenholz, P., Saoud, R., Eggener, S., Ho, M., …, & EAU-YAU Penile and Testis Cancer Working Group (2023). Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00443

Vancouver

Antonelli L, Ardizzone D, Tachibana I, Adra N, Cary C, Hugar L, et al. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.00443

BibTeX
@article{Antonelli2023,
  author = {Antonelli, Luca and Ardizzone, Davide and Tachibana, Isamu and Adra, Nabil and Cary, Clint and Hugar, Lee and Sexton, Wade J and Bagrodia, Aditya and Mego, Michal and Daneshmand, Siamak and Nicolai, Nicola and Nazzani, Sebastiano and Giannatempo, Patrizia and Franza, Andrea and Heidenreich, Axel and Paffenholz, Pia and Saoud, Ragheed and Eggener, Scott and Ho, Matthew and Oswald, Nathaniel and Olson, Kathleen and Tryakin, Alexey and Fedyanin, Mikhail and Naoun, Natacha and Javaud, Christophe and Cazzaniga, Walter and Nicol, David and Gerdtsson, Axel and Tandstad, Torgrim and Fizazi, Karim and Fankhauser, Christian Daniel and EAU-YAU Penile and Testis Cancer Working Group, EAU-YAU Penile and Testis Cancer Working Group},
  title = {Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.23.00443}
}
Kostenlos starten →